Clinical trials: Gender Dysphoria
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Gender Dysphoria, Adult
Comparative Study of Gender Identity Disorder Versus Control
Gender dysphoria is manifested by an internal tension between biological sex and gender, that is, by a non-congruence, in the subjects who suffer from it, between their sex of birth and their social gender identity.
- Trial name
- TRANSIDENT (NCT04935164)
- Testing
- Psychiatric evaluations
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Henri Laborit
Transgender, Gender Incongruence
China Gender-affirming Hormone Therapy Study
Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese…
- Trial name
- CGAHT (NCT05318755)
- Testing
- GAHT for transgender men, GAHT for transgender women
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Gender Dysphoria, Mastectomy
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision…
- Conditions
- Gender Dysphoria, Mastectomy, Hypertrophic Scar
- Trial name
- FMTB Brij (NCT07147166)
- Testing
- Brijjit® BP100-6 and BP-75, Control: Standard of care and normal wound dressing
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Gender Dysphoria
Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria
The aim of the research is to study longitudinally the effects of reassignment hormonotherapy on the connectome of MtF (biological men who are transitioning to the female gender) dysphoric subjects after 6 months of hormone…
- Trial name
- DCHGD (NCT04309760)
- Testing
- MRI
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hôpital le Vinatier
Gender Dysphoria
Brain Health in Transgender Adults
The purpose of this study is to test whether and how a person's brain changes in the first few months after starting gender affirming hormone therapy (GAHT).
- Trial name
- NCT07624747
- Testing
- Magnetic Resonance Imaging, Cognition and Health Tests, Optional Exercise Test
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Gender Dysphoria in Children, Puberty
Skeletal Health and Bone Marrow Composition Among Youth
Children and adolescents experiencing gender dysphoria feel increased distress with the onset of puberty. Gender clinics treat these young adolescents by "blocking" puberty using gonadotropin-releasing hormone (GnRH) agonist…
- Conditions
- Gender Dysphoria in Children, Puberty, Bone Development
- Trial name
- NCT04203381
- Testing
- GnRH Agonist
- Where
- 2 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Amy DiVasta, MD
Gender Dysphoria, Adolescent
Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
Recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (TGD) youth compared to cis-gender youth.
- Trial name
- NCT05726903
- Testing
- Depo-subQ Provera Injectable Product
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Gender Dysphoria
Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans
Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex.
- Trial name
- NCT06615401
- Where
- United States
- Volunteers
- 986 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Gender Incongruence, Cardiovascular Disease (CVD) Risk Factors
Cardiomodulatory Effects of Gender-Affirming Hormone Therapy
Gender-affirming hormone therapy is today a well-established treatment for individuals experiencing gender-incongruence. However, little is known about the long-term effects of gender-affirming hormone therapy on the…
- Trial name
- CARMEN (NCT07128771)
- Where
- Norway
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University Hospital, Akershus
Gender Dysphoria
Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content
Background: Sex hormones are believed to play an important role in the development and progression of cardiovascular disease. However, the gender gap in onset and mortality is not yet completely understood.
- Trial name
- NCT06245681
- Testing
- gender affirming hormone therapy
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Gender Dysphoria, Hormone Therapy Induced Morphologic Change
Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
Background: Gender affirming hormone therapy (GAHT) leads to profound changes in sex hormone levels, carrying a wide range of implications for major physiological processes in the body.
- Trial name
- NCT06291675
- Testing
- gender-affirming hormone therapy
- Where
- Austria
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Gender Dysphoria, Adult, Blood Coagulation
Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study
The goal of this clinical trial is to learn about the effects of different routes of estradiol administration on blood clotting in transgender women starting gender-affirming hormone therapy.
- Conditions
- Gender Dysphoria, Adult, Blood Coagulation, Coagulation Factors, Transgender Persons, M01.777.500
- Trial name
- NCT07145281
- Testing
- Estradiol (E2), Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Gender Dysphoria
Effects of Gender-affirming Hormone Therapy on Transgender People
This prospective cohort study aims to assess the impact of gender-affirming hormone therapy (GAHT) on transgender individuals' physical, psychological, social, and quality of life aspects.
- Trial name
- NCT06022562
- Where
- Taiwan
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Taiwan University
Hypogonadism, Gender Identity Dysphoria
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
It has been known that both estrogen and testosterone are the major sex steroids regulating bone metabolism and other physiological changes in both male and female, respectively.
- Trial name
- NCT06247267
- Testing
- Fortesta, Estradiol
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Gender Dysphoria, Voice Disorder Due to Transsexualism
Investigation of the Perceptual and Acoustic Voice in Trans Man
The aim of the study is to follow acoustic and perceptual voice changes in trans men during hormone therapy and to examine the relationship between psychosocial and vocal characteristics and testosterone measured in routine…
- Conditions
- Gender Dysphoria, Voice Disorder Due to Transsexualism, Transgender Persons, Hormone Replacement Therapy
- Trial name
- NCT05166083
- Testing
- Testosterone Hormon Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Gender Dysphoria
Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria
The current project aims to improve the well-being of trans and nonbinary (TNB) individuals through an online intervention (Trans Care) targeting the reduction of symptoms of gender dysphoria.
- Trial name
- NCT05903911
- Testing
- Trans Care Web App
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Gender Dysphoria
Acoustic and Perceptual Effects of Intonation Training in Gender Diverse People
The aim of this project is to investigate the short- and the longer-term effect of intonation training on vocal characteristics, listener perceptions and patient related outcome measures (PROMS) in gender diverse people using a…
- Trial name
- B6702021001262 (NCT05204732)
- Testing
- Intonation training
- Where
- Belgium
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University Ghent
Transgender Health, Gender Dysphoria
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy.
- Conditions
- Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
- Trial name
- IDENTIFY (NCT04283656)
- Testing
- Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Sleep Disorder, Insulin Resistance
Sleep and IR in Transgender Adolescents
Disordered sleep is a health issue with significant impacts on physical and psychological well-being that has increased in prevalence, but its impact on transgender adolescents has not been fully quantified.
- Conditions
- Sleep Disorder, Insulin Resistance, Gender Dysphoria
- Trial name
- ATP (NCT05489159)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Duke University